

Ref. No: 0923
Date: 08/05/24
Subject: Intra-vitreous Injections / Implants

REQUEST

1. How many of the following intra-vitreous injections / implants has your Trust administered in the four-month period from January to April 2024:

- Aflibercept
- Bevacizumab – Avastin
- Bevacizumab – Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab – Lucentis (pre-filled syringes)
- Ranibizumab – Lucentis (vials)
- Ranibizumab – Ongavia

2. Please provide the number of injections / implants by eye condition for the four-month period from January to April 2024:

Number of Injections / Implants: January to April 2024

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept			
Bevacizumab			
Dexamethasone			
Faricimab			
Ranibizumab - Lucentis			
Ranibizumab - Ongavia			

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such

parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. How many of the following intra-vitreous injections / implants has your Trust administered in the four-month period from January to April 2024:

Treatment	No. Patients
Aflibercept	810
Bevacizumab – Avastin	0
Bevacizumab – Biosimilar	0
Brolucizumab	<5
Dexamethasone	48
Faricimab	366
Fluocinolone acetonide	0
Ranibizumab – Lucentis (pre-filled syringes)	12
Ranibizumab – Lucentis (vials)	0
Ranibizumab – Ongavia	532

2. Please provide the number of injections / implants by eye condition for the four-month period from January to April 2024:

Treatment	Eye Conditions		
	wAMD	DMO	RVO
Aflibercept	<5	81	709
Bevacizumab	0	0	0
Dexamethasone	0	10	21
Faricimab	274	89	<5
Ranibizumab - Lucentis	8	<5	<5
Ranibizumab - Ongavia	372	66	70

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.